Celecoxib induces regression of putative preneoplastic lesions in rat liver

Anticancer Research

Volumn 26, Issue 2 A, 2006, Pages 1271-1280

  Arellanes Robledo, Jaime ^a   Márquez Rosado, Lucrecia ^a   Pérez Carreón, Julio Isael ^a   Fattel Fazenda, Samia ^a   Aguirre García, Jesús ^b   Villa Treviño, Saúl ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b HOSPITAL GENERAL DE MÉXICO   (Mexico)

Author keywords

Celecoxib; Chemoprevention; Hepatocarcinogenesis; Regression

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; CELECOXIB; CYCLIN D1; CYCLINE; CYCLOOXYGENASE 2; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE TRANSFERASE; PROSTAGLANDIN E2;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER MORTALITY; CANCER RISK; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; GROWTH INHIBITION; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER FUNCTION; LIVER TUMOR; MALE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; RAT; RISK REDUCTION; SPECTROPHOTOMETRY; TUMOR REGRESSION;

ANIMALS; CELL GROWTH PROCESSES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MALE; ORGAN SIZE; PRECANCEROUS CONDITIONS; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES;

EID: 33645818385     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Mcglynn KA, Tsao L, Hsing AW, Devesa SS and Fraumeni JF Jr: International trends patterns of primary liver cancer. Int J Cancer 94: 290-296, 2001.
2. Subbaramaiah K and Dennenderg AJ: Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24: 96-102, 2003.
3. Gupta S, Adhami VM, Subbarayan M, MacLennan GT, Lewin JS, Hafeli UO, Fu P and Mukhtar H: Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 64: 3334-3343, 2004.
4. Grubbs CJ, Lubet RA, Koki AT, Leahy KM, Masferrer JL, Steel VE, Kellof GL, Hill DL and Seibert K: Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)- nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fisher-344 rats. Cancer Res 60: 5599-5602, 2000.
5. Jacoby RF, Seibert K, Cole CE, Kelloff G and Lubet RA: The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 60: 5040-5044, 2000.
6. Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S, Seibert K and Rao CV: Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 60: 293-297, 2000.
7. Harris RE, Alshafie GA, Abou-Issa H and Seibert K: Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 60: 2101-2103, 2000.
8. Wilgus TA, Koki AT, Zweifel BS, Rubal PA and Oberyszyn TM: Chemotherapeutic efficacy of topical celecoxib in a murine model of ultraviolet light B-induced skin cancer. Mol Carcinog 38: 33-39, 2003.
9. 2 pathway in human cholangiocarcinoma cell lines. World J Gastroenterol 9: 1302-1306, 2003.
10. Kern MA, Schubert D, Sahi D, Schöneweifs MM, Moll I, Haugg AM, Dienes HP, Breuhahn K and Schirmacher P: Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 36: 885-894, 2002.
11. Zhang Z, Lai GH and Sirica AE: Celecoxib-induce apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology 39: 1028-1037, 2004.
12. Leng J, Han C, Demetris AJ, Michalopoulos GK and Wu T: Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through AKT activation: evidence for AKT inhibition in celecoxib-induced apoptosis. Hepatology 38: 756-768, 2003.
13. Grösch S, Tegeder I, Neiderberger E, Bräutigam L and Geisslinger G: COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 15: 2742-2744, 2001.
14. Márquez-Rosado L, Trejo-Solís MC, García-Cuellar C and Villa-Treviño S: Celecoxib, a cyclooxygenase-2 inhibitor, prevents induction of liver preneoplastic lesions in rats. J Hepatol 43: 653-660, 2005.
15. Steinbach G, Lynch PM, Phillips RKS, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK and Levin B: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946-1952, 2000.
16. Semple-Roberts E, Hayes MA, Armstrong D, Becker RA, Racz WJ and Farber E: Alternative methods of selecting rat hepatocellular nodules resistant to 2-acetylaminofluorene. Int J Cancer 40: 643-645, 1987.
17. Rutenburg AM, Kim H, Fischbein JW, Hanker JS, Wasserkrug HL and Seligman AM: Histochemical and ultrastructural demonstration of γ-glutamil transpeptidase activity. J Histochem Cytochem 17: 517-526, 1969.
18. Reitman S and Frankel S: A colorimetric method for determination of serum oxaloacetic and glutamic pyruvic transaminases. Am J Clin Pathol 28: 56-63, 1957.
19. Stewart HL, Williams G, Keysser CH, Lombart LS and Montali RJ: Histologic typing of liver tumors of the rat. J Natl Cancer Inst 64: 179-206, 1980.
20. 2 levels in patients with brain tumors before and after tumor removal. J Neuro-Oncol 57: 147-150, 2002.
21. Won YK, Ong CN, Shi XL and Shen HM: Chemopreventive activity of parthenolide against UVB-induced skin cancer and its mechanisms. Carcinogenesis 25: 1449-1458, 2004.
22. Donnellan R and Chetty R: Cyclin D1 and human neoplasia. J Clin Pathol Mol Pathol 51: 1-7, 1998.
23. Williams CS, Mann M and DuBois RN: The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18: 7908-7916, 1999.
24. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT and Masferrer JL: Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 62: 625-631, 2002.
25. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 700: 57-70, 2000.
26. Williams CS, Watson AJ, Sheng H, Helou R, Shao J and DuBois RN: Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vivo and in vitro models. Cancer Res 60: 6045-6051, 2000.
27. 2 administration. Carcinogenesis 24: 985-990, 2003.
28. kipl and cell cycle arrest. Cancer Res 64: 1369-1374, 2004.
29. Kelman Z: PCNA: structure, function and interactions. Oncogene 14: 629-640, 1997.
30. Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, Newman RA, Cordon-Cardo C, Thaler HT and Dannenberg AJ: Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 11: 1999-2007, 2005.
31. Hendrich S, Campbell HA and Pilot HC: Quantitative stereological evaluation of four histochemical markers of altered foci in multistage hepatocarcinogenesis in the rat. Carcinogenesis 8: 1245-1250, 1987.
32. Yi H, Wang X, Miao JY, Du JP, Pan YL, Liu N, Zhang XM and Fan DM: Protective effect of selective cyclooxygenase-2 inhibitor on alcohol-induced liver injury in rats. Zhonghua Gan Zang Bing Za Zhi 11: 663-666, 2003.
33. Ensminger W, Knol J, DeRemer S, Wilkinson E, Walker S, Williams D and Maybaum J: Effects of dexamethasone or celecoxib on biliary toxicity after hepatic arterial infusion of 5-fluorodeoxyuridine in a canine model. Cancer Res 64: 311-315, 2004.
34. Tarao K, Rino Y, Ohkawa S, Shimizu A, Tamai S, Miyzkawa K, Imada T, Shindo K, Okamoto N and Totsuka S: Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. Cancer 86: 589-595, 1999.
35. Lee JS, Chu IS, Mikaelyan A, Calvisi DF, Heo J, Reddy JK and Thorgeirsson SS: Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 36: 1306-1311, 2004.